



GROWTH THAT COMPOUNDS

Promised synergies need a ledger

A deal promise is not a result. Track its unit, baseline, timing, and later statement before calling a synergy realized.

Sinan Isoglu, MBA (Quantic)

Commercial growth leader, lecturer and doctoral researcher

PUBLISHED

28 August 2026

READING TIME

11 min

WORDS

2,400

<https://isoglu.com/insights/journal/promised-synergies-need-a-ledger/>

Management summary	2
A promise has a unit	3
Why is the M&A synergy panel twelve discrete transaction rows rather than an industry average?	4
How should integration committees track individual cost line items before aggregate rates?	6
What the later number does not say	6
Build the ledger before the deal closes	7
Why must the realization verdict remain unresolved until verified by post-close audits?	8
Where are the empirical boundaries of M&A synergy accounting?	8
References	9

MANAGEMENT SUMMARY

A synergy number becomes useful only when its unit, baseline, timing, dependency, and source stay attached to it. This note follows twelve large transactions from a public announcement to a later public record. The panel is deliberately bounded, not a census and not a pass-rate denominator. One later filing reports about US\$800 million of annual cost synergies by the end of 2025 against an approximately US\$1 billion target by the end of 2026. Another moves from a US\$1 billion target to a US\$1.5 billion annual run-rate without a component bridge. Other rows show a milestone, a revised target, a buyer-side impact, an explicit accounting exclusion, or no quantified result. The practical output is a ledger that lets a board compare like with like and label the rest unresolved.

Keywords: M&A · Synergy tracking · Post-merger integration · Corporate development · Measurement

The deck says US\$1 billion of synergies. The later filing says about US\$800 million of annual cost synergies by the end of 2025, against an approximately US\$1 billion target by the end of 2026. The tempting calculation is 80 percent. The defensible answer is different: the later statement is a management-reported progress figure, the target date has moved, and the public record does not supply the bridge a percentage would need.

That is not a technicality. A deal promise and a later statement are different evidence objects. If the unit, baseline, timing, scope, or owner changes, the number may still be important, but it is not the result of the first number. The work is to keep those differences visible before a board turns a progress sentence into a score.

The operating discipline is close to a living business-case control loop: every number keeps an owner, a timing rule, and a next review.

A promise has a unit

The first field in a synergy ledger is not the amount. It is the kind of amount.

Transaction value is not a synergy. Purchase consideration is not a synergy. Sale proceeds are not a synergy. Operating contribution, free-cash-flow accretion, an integration cost, an EPS effect, and a run-rate cost reduction may all appear in the same announcement or filing, but they answer different questions. A ledger that drops them into one column has already decided that they are comparable.

Pfizer's Seagen record shows why the time field belongs beside the amount. The 2023 announcement said "nearly", not approximately: Pfizer expected "nearly 1 billion in cost efficiencies in the third full year after the completion of the transaction". Pfizer's 2025 Form 10-K later reported approximately US\$800 million of annual cost synergies by the end of 2025 and an approximately US\$1 billion target by the end of 2026. The later figure is useful. It is not an audited realization rate against the earlier sentence. Its source, timing, and target status need to travel with it.

That is also why the integration plan spends what the deal bought treats the case as a controlled sequence rather than a headline.

Chevron's Hess record makes the same point with a revision. The transaction announcement described about US\$1 billion of pre-tax run-rate cost synergies within a year of closing. The second-quarter 2026 results release later described US\$1.5 billion of annual run-rate synergies related to Hess. This page previously said a 2025 Form 10-K had reported the initial target achieved; no such filing is cited or held here, so the sentence is removed rather than left resting on a document nobody can open. That is a management series with an upward revision. Without a category bridge or a common baseline, it cannot be written as 150 percent realization.

ConocoPhillips and Marathon Oil add a different boundary. The announcement described at least US\$500 million of run-rate cost and capital savings in the first full year. The later filing reported more than US\$1 billion of run-rate synergies and about US\$1 billion of separate one-time benefits, primarily related to tax effects. The two later fields may both matter to the integration case. They are not one recurring synergy number.

Newmont and Newcrest offer the cleanest milestone and still require a label. Newmont announced US\$500 million of annual pre-tax synergies within 24 months. Its third-quarter 2024 results release reported a US\$500 million annual run-rate more than a year ahead of schedule and described the figure as a management estimate rather than a GAAP or non-GAAP measure. That supports a management-reported milestone. It does not create an independently reconstructed benefit.

Why is the M&A synergy panel twelve discrete transaction rows rather than an industry average?

To make the comparison inspectable, I froze a small public panel. A row had to meet all of these conditions: announcement in 2023 or 2024, at least one US or European participant, a headline value of at least US\$10 billion in the primary transaction record, completion by 28 August 2026, and a held completion record plus later public report or regulated filing. The value screen is the selection rule. It is not a claim that transaction value predicts synergy.

The panel includes acquisitions, mergers, a control transfer, and a business carveout. It keeps enterprise value, equity value, consideration, proceeds, operating contribution, and synergy fields separate. Its states describe the public record, not the quality of management execution.

Table 1 Why is the M&A synergy panel twelve discrete transaction rows rather than an industry average?

Deal	Announcement value	Later public signal	Ledger state
Pfizer and Seagen	US\$43 billion enterprise value	About US\$800 million annual cost synergies by 2025, with an approximately US\$1 billion 2026 target	Revised, partial management result
Chevron and Hess	US\$53 billion equity value, US\$60 billion enterprise value	Initial US\$1 billion target reported achieved, later US\$1.5 billion annual run-rate	Confirmed then revised management series
ConocoPhillips and Marathon Oil	US\$22.5 billion enterprise value	More than US\$1 billion run-rate synergies plus separate one-time benefits	Revised management run-rate result
Newmont and Newcrest	A\$28.8 billion enterprise value	US\$500 million annual run-rate reported ahead of schedule	Confirmed management milestone
ONEOK and Magellan	US\$18.8 billion including assumed debt	US\$160 million to US\$190 million of combined first-year impacts	Later quantified, no initial baseline
Extra Space and Life Storage	US\$47 billion total enterprise value	Later filing gives merger operating and transition fields, not a same-scope bridge	Not comparable
HPE and Juniper	Approximately US\$14 billion equity value	At least US\$600 million of Juniper-related cost synergies targeted by fiscal 2028, with investment required	Later target, not realization
DSV and DB Schenker	EUR14.3 billion enterprise value	DKK800 million of 2025 synergy-related impact and a DKK9 billion annual target for 2027	Buyer-side impact, no seller baseline
Carrier and Viessmann	EUR12 billion	Proxy says cost-synergy targets were delivered, without amount or bridge	Target-delivery milestone
Gallagher and AssuredPartners	US\$13.45 billion gross consideration	Pro forma exhibit excludes expected synergies and the costs needed to achieve them	Not comparable
EQT and Equitrans	Combined enterprise value above US\$35 billion	Later filing gives operating and accounting fields, not a same-scope synergy result	Not comparable

Deal	Announcement value	Later public signal	Ledger state
BlackRock and HPS	Approximately US\$12 billion	Later filing gives operating-profile and accounting fields, not a quantified synergy result	Not quantified

Table from this essay. Sources and interpretation are given in the article.

The panel does not answer how often large mergers succeed. Twelve is the number of rows a reader can inspect under this rule. It is not a market denominator. A percentage formed by dividing a count of states by twelve would be a new claim, and the public records do not authorize it.

How should integration committees track individual cost line items before aggregate rates?

The useful object is not a dashboard with a green cell. It is a row that makes a later calculation earn its right to exist.

Figure 1 The row before the rate

DEAL	PROMISE DOCUMENT AND DATE	UNIT AND BASELINE	WHAT DEPENDS, WHO OWNS?	TARGET DATE	LATER DOCUMENT AND DATE	LATER FIELD	SAME SCOPE?	VERDICT
Name the transaction and structure.	What was said, where, and when?	Run-rate, sum, revenue or cost?	What has to happen, who owns it?	Visible when?	What is the next public record?	Copy it, do not relabel.	Yes, partly, no, open?	Confirmed, revised, unclear?

Do not calculate until the unit, baseline, timing, and perimeter are the same. A blank bridge is a reporting state, not a zero.

Author's own worksheet, based on the frozen P02 public panel. The worksheet is a control instrument, not a validated management system.

The worksheet forces a question that a percentage hides: same as what? If the promise was an annual run-rate and the later statement is a three-year aggregate, the fields may belong in the same deal history but not in the same arithmetic. If the promise was cost and the later statement is revenue, the difference is not a rounding issue. If the target date moved, the date is part of the result.

What the later number does not say

The later record often contains a number that looks close enough. Three traps recur.

Operating contribution is not synergy realization. A filing can report revenue or operating income contributed by the acquired business. That tells you something about the business perimeter and the reporting period. It does not isolate the benefit created by combining two operations.

Integration cost is not the inverse of synergy. A cost to integrate, retain people, or separate a business may be necessary to capture a benefit. It belongs in the investment case. It should not be subtracted from a later operating field unless the model defines the relation and keeps the horizons consistent.

Silence is not zero. Extra Space's later filing gives merger-associated revenue, expense, and transition-cost fields without a same-scope bridge to its US\$100 million annual run-rate operating synergy target. Gallagher's pro forma exhibit explicitly excludes expected cost savings, operating synergies, revenue enhancements, and the costs needed to achieve them. Those are useful negative disclosures. Neither says that the promise failed.

The same rule applies to the rows with no quantified result. BlackRock's later HPS filing supplies operating and accounting measures. DSV's later report supplies a buyer-side impact and a later target, while the seller's transaction announcement supplied no matching synergy baseline. HPE's later filing introduces a target that was not in the announcement. These are reporting boundaries, not blanks to be filled with an assumption.

Build the ledger before the deal closes

The ledger is useful before the first integration meeting because the original promise is easiest to lose after the close. I would record nine fields.

- 1 Deal and structure. Acquisition, merger, majority-control transfer, or carveout. Keep the reporting perimeter visible.
- 2 Promise document and date. Announcement, merger filing, investor presentation, or another primary record. Save the original currency and wording in the source record.
- 3 Unit and baseline. Cost, revenue, cash flow, capital, headcount, capacity, or another defined measure. Record whether the amount is annual, cumulative, run-rate, or one-time.
- 4 Dependency and owner. Procurement, systems, footprint, pricing, cross-sell, talent, or another mechanism. Name the team that can observe it.
- 5 Target date. A date turns a promise into a testable event. If the date moves, preserve the old date and add the new one.
- 6 Later document and date. Annual report, results release, proxy, or another public record. Do not let a later document inherit the first document's label automatically.
- 7 Later field. Copy the later amount in its source unit. Keep operating contribution, accounting fields, integration cost, and synergy fields separate.
- 8 Same-scope test. Compare unit, baseline, currency, timing, perimeter, and category. Mark the comparison partial when one of them is missing.
- 9 Verdict. Use a small vocabulary: confirmed, revised, not quantified, not comparable, or unresolved. The vocabulary describes the record. It does not rate the deal team.

This process also protects a good result. ONEOK's later release reports approximately US\$160 million to US\$190 million of combined first-year cost and initial commercial synergy impacts after its Magellan acquisition. That is a meaningful management-reported result. The announcement had named cost, operational, tax, and commercial

categories without one quantified baseline, so the ledger should preserve the result and its comparison limit at the same time.

Why must the realization verdict remain unresolved until verified by post-close audits?

The pressure to publish a binary result is understandable. A board wants to know whether the thesis worked. But a public record can be precise about a different thing: what was promised, what was later said, and whether the two can be reconciled.

That is why the panel carries a state rather than a score. A management milestone can be worth acting on while still being management-reported. A revised number can be better information while still not being comparable with the first target. A filing can be silent because the company reports the measure elsewhere, because the target is not a required disclosure, or because the scope has changed. The ledger records that the bridge was not found. It does not invent the bridge.

For the board, the questions are short:

- What was the original unit and baseline?
- Has the target date passed, and did the perimeter stay the same?
- Is the later number recurring, aggregate, operating, accounting, or one-time?
- Is it a company statement, an audited line, or an inference?
- If the fields do not match, what decision is being made without the missing bridge?

The last question is the point. A ledger does not make a synergy real. It makes the decision-maker notice which part is real, which part is reported, and which part is still a promise.

Where are the empirical boundaries of M&A synergy accounting?

This is a public, receipt-bounded panel of twelve transactions announced in 2023 or 2024 and completed by 28 August 2026. It is not a census of M&A, a representative sample, or a synergy success rate. Management-reported milestones remain attributed as such. A later public filing that does not provide a same-scope bridge is coded as not quantified, not comparable, or unresolved, never as zero. The panel does not contain private company data, customer data, or a claim about any deal outside its named records.

Evidence base. The analytical frame also draws on these additional sources: Pfizer 2023; Pfizer 2026; Chevron 2023; Chevron 2026; ConocoPhillips 2024; Newmont 2023; ONEOK 2024; Extra Space Storage 2025; Hewlett Packard Enterprise 2025; DSV 2026; Carrier 2025; Arthur J. Gallagher & Co 2025; BlackRock 2026. The links identify the exact works; they support the mechanisms and boundary conditions discussed here, not every claim in isolation.

REFERENCES

- Pfizer. (2023). Pfizer invests \$43 billion to battle cancer. <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer>
- Pfizer. (2026). 2025 Form 10-K. <https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm>
- Chevron. (2023). Chevron announces agreement to acquire Hess. <https://www.chevron.com/newsroom/2023/q4/chevron-announces-agreement-to-acquire-hess>
- Chevron. (2026). Second-quarter 2026 results, Exhibit 99.1. <https://www.sec.gov/Archives/edgar/data/93410/000009341026000162/a06302026ex9918-k.htm>
- ConocoPhillips. (2024). ConocoPhillips to acquire Marathon Oil. <https://www.conocophillips.com/news-media/story/conocophillips-to-acquire-marathon-oil-corporation-in-all-stock-transaction-provides-shareholder-distribution-update/>
- Newmont. (2023). Newmont enters into definitive agreement to acquire Newcrest. <https://newmont.com/investors/news-release/news-details/2023/Newmont-Enters-into-Definitive-Agreement-to-Acquire-Newcrest/default.aspx>
- ONEOK. (2024). 2023 full-year results. <https://ir.oneok.com/news-and-events/press-releases/2024/02-26-2024-211611105>
- Extra Space Storage. (2025). 2024 Form 10-K. <https://www.sec.gov/Archives/edgar/data/1289490/000162828025009060/exr-20241231.htm>
- Hewlett Packard Enterprise. (2025). 2025 Form 10-K. <https://investors.hpe.com/~media/Files/H/HP-Enterprise-IR/documents/governance/annual-report-on-form-10K-2025.pdf>
- DSV. (2026). 2025 annual report. <https://investor.dsv.com/news-releases/news-release-details/dsv-1164-2025-annual-report>
- Carrier. (2025). 2025 definitive proxy statement. <https://www.sec.gov/Archives/edgar/data/1783180/000178318025000014/carr-20250225.htm>
- Arthur J. Gallagher & Co. (2025). AssuredPartners pro forma information. <https://www.sec.gov/Archives/edgar/data/354190/000162828025046542/projectboomerangnarrativ.htm>
- BlackRock. (2026). 2025 Form 10-K acquisition note. <https://www.sec.gov/Archives/edgar/data/2012383/000119312526071966/R15.htm>

END OF ESSAY

HOW TO CITE THIS ESSAY

Isoglu, S. (2026, August 28). Promised synergies need a ledger. Sinan Isoglu.
<https://isoglu.com/insights/journal/promised-synergies-need-a-ledger/>

KEEP READING

Growth that compounds

The megadeal wave meets the size effect

<https://isoglu.com/insights/journal/the-megadeal-wave-meets-the-size-effect/>

Growth that compounds

Knowledge transfer is asset retention with a receiving context

<https://isoglu.com/insights/journal/knowledge-transfer-is-asset-retention-with-a-receiving-context/>

Growth that compounds

The playbook study never asked who made the tools

<https://isoglu.com/insights/journal/the-playbook-study-never-asked-who-made-the-tools/>



Sinan Isoglu, MBA (Quantic)

Commercial growth leader, lecturer and doctoral researcher